Thromboembolic diseases are one of the leading causes of morbidity and mortality
worldwide. For a long time, heparin and Vitamin K antagonist (VKA) drugs were used for …

Intracerebral haemorrhage (ICH) accounts for half of the disability-adjusted life years lost
due to stroke worldwide. Care pathways for acute stroke result in the rapid identification of …

Andexanet alfa (AA) is a recombinant factor Xa competing for binding with factor Xa
inhibitors, thereby reversing their anticoagulation effects. Since 2019, it has been approved …

BACKGROUND Anticoagulation is essential for the treatment and prevention of
thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) …

Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) are widely
applied for surgical procedures and extracorporeal therapies, which, however, suffer …

Background There has been debate on the use of intravenous thrombolysis (IVT) in patients
with ischemic stroke and the recent use of direct oral anticoagulants (DOACs). Studies have …

Background Both andexanet alfa and four‐factor prothrombin complex concentrate (4F‐
PCC) are clinically applied reversal agents for direct factor Xa inhibitors (FXaIs) in …

Introduction Cardiac patients on antiplatelets or oral anticoagulation undergoing emergent
cardiac surgery without appropriate washout periods are at increased risk for developing …

There has been a landmark shift in the last several decades in the management and
prevention of thromboembolic events. From the discovery of parenteral and oral agents …

There are potential concerns related to bleeding caused by oral anticoagulants, especially
in the elderly. Andexanet alfa has been authorized for use to reverse the effects of oral …